Answers are grounded in this paper and cite their sources.
Case series shows cardiac stabilization and reduced steroid dependence in eosinophilic myocarditis patients treated with mepolizumab, suggesting improved long-term clinical outcomes.
Eosinophilic myocarditis (EM) is a rare disease associated with significant morbidity and mortality. This case series follows the clinical courses of 3 patients with EM. The use of mepolizumab, an anti-interleukin-5 monoclonal antibody, as an adjunctive treatment was associated with stabilization of cardiac function and improved long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Trovato et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: